quinta-feira, 8 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Stock market today: Dow, S&P 500, Nasdaq rise as Fed meeting kicks off, JOLTS data shows openings rose

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq rise as Fed meeting kicks off, JOLTS data shows openings rose US stocks turned into the green Tuesday morning as the Federal Reserve's December policy meeting kicked off and federal data showed job openings unexpectedly ticked higher even as layoffs jumped…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Would be looking for a new Fed chair to immediately move to cut rates

    80% confidence

  • Luxury homebuilding business remains differentiated despite market conditions

    80% confidence

  • Moscow is planning to continue sending uninterrupted fuel supplies to India

    80% confidence

  • Housing market is experiencing soft demand and choppy conditions this year

    80% confidence

  • Americans' affordability concerns are a con job

    80% confidence

  • Snacks business continues to weather category softness but brands remain highly relevant

    80% confidence

  • It would be irresponsible to set out plans for the next six months regarding monetary policy

    80% confidence

  • Consumers remain intentional in their shopping behaviors with at-home-cooking trends continuing to benefit brands

    80% confidence

Data points we hold from this source

Dow Jones Industrial Average · stock movement0.35 percent
Donald Trump · approval rating economy39.8 percent
Donald Trump · disapproval rating economy57.6 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com